EXCLUSIVE: Adial Pharmaceuticals Announces Topline Results For ONWARD Phase 3 Trial For AD04 In Patients With Alcohol Use Disorder
Charlottesville, VA – July 20, 2022 – Adial Pharmaceuticals, Inc. (NASDAQ:
ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical
company focused on developing